Indication
Recurrent Follicular Lymphoma
23 clinical trials
29 products
10 drugs
Clinical trial
Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With CD19+ B-Cell Lymphoproliferative NeoplasmsStatus: Active (not recruiting), Estimated PCD: 2024-12-30
Product
BendamustineDrug
cyclophosphamideProduct
EtoposideDrug
fludarabineClinical trial
A Phase I/II Study of the PD-1 Antibody Nivolumab in Combination With Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
LenalidomideProduct
NivolumabClinical trial
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
IbrutinibClinical trial
A Phase I Study of Venetoclax + Lenalidomide + Rituximab Hyaluronidase in Relapsed or Refractory (R/R) Indolent Non-Hodgkin's Lymphoma (iNHL).Status: Recruiting, Estimated PCD: 2025-03-31
Product
VenetoclaxDrug
VarlilumabClinical trial
A Phase I/II Study of Lenalidomide and Obinutuzumab (GA101) in Relapsed Indolent Non-Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2023-01-23
Product
ObinutuzumabClinical trial
A Phase 1 Study of Pembrolizumab Plus Vorinostat for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-06-23
Product
PembrolizumabClinical trial
Randomized Phase II Trial in Early Relapsing or Refractory Follicular LymphomaStatus: Recruiting, Estimated PCD: 2025-12-31
Product
VorinostatClinical trial
A Phase I Study of Pevonedistat (MLN4924, TAK924) in Combination With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-06-22
Clinical trial
Phase II Study of Anti-CD20 Antibody Therapy Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular and Diffuse Large B-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-12-19
Product
PevonedistatProduct
CyclophosphamideProduct
DoxorubicinProduct
PrednisoneProduct
UmbralisibProduct
VincristineClinical trial
Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With Ibrutinib and Local Radiation in Relapsed or Refractory Low-Grade Follicular LymphomaStatus: Completed, Estimated PCD: 2023-05-18
Product
SD-101Clinical trial
A Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-cell Non-Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase II Study of Brentuximab Vedotin Plus Bendamustine for Relapsed/Refractory Follicular LymphomaStatus: Recruiting, Estimated PCD: 2024-12-01
Product
Brentuximab VedotinClinical trial
Phase 1a/1b Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells (MC10029) in Subjects With Relapsed or Refractory BAFFR-Expressing B-Cell Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2040-12-31
Clinical trial
A Phase 1b/2 Investigator Initiated Study of RCHOP in Combination With Selinexor (KPT-330) in B Cell Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2025-12-01
Drug
SelinexorClinical trial
A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell LymphomasStatus: Active (not recruiting), Estimated PCD: 2023-05-03
Drug
mFOLFOX6Product
PralatrexateClinical trial
A Phase I/IB Pilot Study of CC-486 Combined With Lenalidomide and Obinutuzumab for Relapsed/Refractory Indolent B-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-04-01
Product
AzacitidineClinical trial
A Phase I Study Evaluating Copanlisib in Combination With R-GCD (Gemcitabine, Carboplatin, Dexamethasone, and Rituximab) With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and High-Risk Follicular LymphomaStatus: Terminated, Estimated PCD: 2022-04-27
Drug
pegfilgrastimClinical trial
Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation and Anti-PD-1 Antibody (Pembrolizumab) for Patients With Non-Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Product
Dendritic Cell TherapyClinical trial
Optimizing Post-allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using IbrutinibStatus: Completed, Estimated PCD: 2021-11-18
Clinical trial
A Pilot Study of Loncastuximab Tesirine in Specific Populations of Relapsed/Refractory B-Cell MalignanciesStatus: Recruiting, Estimated PCD: 2025-12-15
Product
Loncastuximab TesirineClinical trial
A Phase I Trial of CD19-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells Genetically Engineered to Secrete Interleukin 12 (IL-12) and With a Truncated Human Epidermal Growth Factor Receptor (EGFRt) in Patients With Relapsed or Refractory CD19+ Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2027-06-15
Clinical trial
A Phase 1/2 Study of Tazemetostat With Umbralisib and Ublituximab in Patients With Relapsed/Refractory Follicular LymphomaStatus: Withdrawn, Estimated PCD: 2024-12-15
Product
TazemetostatProduct
UblituximabClinical trial
Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-Cell Treatment in Patients With Hematologic MalignanciesStatus: Active (not recruiting), Estimated PCD: 2025-04-05
Drug
T-VECProduct
CopanlisibDrug
GemcitabineDrug
AN0025Drug
lenalidomide